School of Psychology, University of Sydney, Sydney, New South Wales, Australia.
PLoS One. 2012;7(2):e30777. doi: 10.1371/journal.pone.0030777. Epub 2012 Feb 15.
There is evidence that heart rate variability (HRV) is reduced in major depressive disorder (MDD), although there is debate about whether this effect is caused by medication or the disorder per se. MDD is associated with a two to fourfold increase in the risk of cardiac mortality, and HRV is a robust predictor of cardiac mortality; determining a direct link between HRV and not only MDD, but common comorbid anxiety disorders, will point to psychiatric indicators for cardiovascular risk reduction.
To determine in physically healthy, unmedicated patients whether (1) HRV is reduced in MDD relative to controls, and (2) HRV reductions are driven by MDD alone, comorbid generalized anxiety disorder (GAD, characterized by anxious anticipation), or comorbid panic and posttraumatic stress disorders (PD/PTSD, characterized by anxious arousal).
DESIGN, SETTING, AND PATIENTS: A case-control study in 2006 and 2007 on 73 MDD patients, including 24 without anxiety comorbidity, 24 with GAD, and 14 with PD/PTSD. Seventy-three MDD and 94 healthy age- and sex-matched control participants were recruited from the general community. Participants had no history of drug addiction, alcoholism, brain injury, loss of consciousness, stroke, neurological disorder, or serious medical conditions. There were no significant differences between the four groups in age, gender, BMI, or alcohol use.
HRV was calculated from electrocardiography under a standardized short-term resting state condition.
HRV was reduced in MDD relative to controls, an effect associated with a medium effect size. MDD participants with comorbid generalized anxiety disorder displayed the greatest reductions in HRV relative to controls, an effect associated with a large effect size.
Unmedicated, physically healthy MDD patients with and without comorbid anxiety had reduced HRV. Those with comorbid GAD showed the greatest reductions. Implications for cardiovascular risk reduction strategies in otherwise healthy patients with psychiatric illness are discussed.
有证据表明,在重度抑郁症(MDD)患者中心率变异性(HRV)降低,尽管关于这种影响是由药物还是疾病本身引起的存在争议。MDD 患者发生心脏性死亡的风险增加 2 至 4 倍,而 HRV 是心脏性死亡的一个强有力的预测指标;确定 HRV 与 MDD 之间的直接联系,不仅是 MDD,还有常见的共病焦虑障碍,将指向降低心血管风险的精神指标。
在身体健康、未用药的患者中确定(1)MDD 患者的 HRV 是否低于对照组,以及(2)HRV 的降低是由 MDD 单独引起的,还是由共病广泛性焦虑障碍(GAD,以焦虑预期为特征)或共病惊恐障碍和创伤后应激障碍(PD/PTSD,以焦虑发作为特征)引起的。
设计、地点和患者:2006 年至 2007 年进行的一项病例对照研究,纳入了 73 名 MDD 患者,其中 24 名无焦虑共病,24 名患有 GAD,14 名患有 PD/PTSD。73 名 MDD 患者和 94 名年龄和性别匹配的健康对照参与者从普通人群中招募。参与者无药物滥用、酗酒、脑损伤、意识丧失、中风、神经障碍或严重疾病史。四组患者在年龄、性别、BMI 或饮酒方面无显著差异。
HRV 是从心电图在标准化的短期静息状态下计算得出的。
与对照组相比,MDD 患者的 HRV 降低,这种效应与中等效应大小相关。与对照组相比,共病广泛性焦虑障碍的 MDD 患者 HRV 降低幅度最大,这种效应与大效应大小相关。
未用药、身体健康的 MDD 患者,无论是否共病焦虑,其 HRV 均降低。共病 GAD 的患者 HRV 降低幅度最大。讨论了在患有精神疾病的其他健康患者中实施心血管风险降低策略的意义。